- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
NICE says Roche’s skin cancer drug not cost effective
6 September 2016 • Author: Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) does not recommend cobimetinib (Cotellic, Roche) with vemurafenib (Zelboraf, Roche) for people with advanced BRAF V600 mutation-positive melanoma that has spread and can’t be surgically removed.
The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year.
In June NICE published final guidance recommending dabrafenib with trametinib, which extended life by an average of 6 months in a clinical trial, for the same patient group.
Cobimetinib costs £4275.67 per 28 days and vemurafenib costs £7000 per 28 days. If it had been recommended vemurafenib would have been provided at a discount that is commercial in confidence.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics